



Advances in Drug Targeting for Central Nervous System Disease

Guest Editors:

Dr. Ivana Cacciatore

Dipartimento di Farmacia,
Università degli Studi “G.
D’Annunzio”, Via dei Vestini 31,
66100 Chieti, Italy

**Dr. Anna Wiktorowska-
Owczarek**

Department of Pharmacology
and Toxicology, Medical
University of Lodz, 7/9
Zeligowskiego, 90-752 Lodz,
Poland

Dr. Sokołowska Paulina

Department of Pharmacology
and Toxicology, Medical
University of Lodz, 7/9
Zeligowskiego, 90-752 Lodz,
Poland

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors

Currently available drugs offer temporary relief from the symptoms of the neurodegenerative disorder, but they do not arrest or reverse the disease. Adverse effects and resistance to traditional therapies require looking for new options. CNS diseases are multifaceted disorders with diverse and not fully understood pathophysiological mechanisms, e.g., the development of inflammatory processes, oxidative and endoplasmic reticulum stress, disturbance of neuronal-glial communication. The pathological processes are associated with specific signaling pathways, and their elements can become strategic points for development of new drugs and for new applications of already approved.

This Special Issue of *Pharmaceutics* titled “**Advances in Drug Targeting for Central Nervous System Diseases**”, will gather discoveries of new drug targets, drug formation and targeted delivery with emphasis on strategies that may alter signaling pathways involved in pathological processes of CNS diseases to stop their progress or even prevent them. Research papers and Reviews on drugs already approved and new molecules are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma